CJC-1295 vs Tesamorelin
Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.
CJC-1295 and Tesamorelin are both growth hormone peptides that come up together constantly. This is a side-by-side comparison on the data that actually matters — evidence tier, FDA status, human trials, and how to source each safely — not hype. It is for research and educational purposes only.
CJC-1295 vs Tesamorelin: side-by-side
| CJC-1295 | Tesamorelin | |
|---|---|---|
| Evidence tier | Tier 4 | Tier 1 |
| FDA status | Not FDA Approved | FDA Approved |
| Human RCTs | 0 | 6 |
| Subjects enrolled | 0 | 800 |
| Animal studies | 12 | 15 |
| Category | growth hormone | growth hormone |
| Half-life | Modified GRF 1-29 has a short half-life (minutes); the DAC variant is reported in days. | Approximately 25-40 minutes. |
| Community logs | 1 | 0 |
Key differences
Tesamorelin rests on stronger human evidence (Tier 1) than CJC-1295 (Tier 4) — that means more confidence its observed effects are real rather than artefacts of weaker study designs. Tesamorelin is FDA approved for specific uses, while CJC-1295 is not fda approved and treated as a research compound in the US.
CJC-1295 has 0 human trials on record (0 subjects) versus Tesamorelin's 6 (800 subjects). Evidence tiers are a shorthand for how strong that human data is — see our guide to understanding peptide evidence tiers for how to weigh them.
What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH 1-29), commonly studied alongside ghrelin-mimetic secretagogues. A DAC (drug affinity complex) variant is designed for an extended half-life. It is not FDA-approved and lacks published human efficacy randomized controlled trials; mechanistic data… Full CJC-1295 breakdown →
What is Tesamorelin?
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog approved by the FDA (as Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. It is supported by phase 3 randomized controlled trials for that specific indication. It is a prescription medication and is… Full Tesamorelin breakdown →
Where to buy CJC-1295 or Tesamorelin safely
Both are sold by research-chemical suppliers, not pharmacies, so the source matters as much as the compound. Before buying either, vet sellers on third-party lab testing and enforcement history in the ranked directory of trusted peptide sellers — or jump straight to vetted sources for CJC-1295 or Tesamorelin. PeptidesHub does not sell either compound.
Frequently asked questions
CJC-1295 and Tesamorelin are both growth hormone peptides. Tesamorelin rests on stronger human evidence (Tier 1) than CJC-1295 (Tier 4) — that means more confidence its observed effects are real rather than artefacts of weaker study designs. Tesamorelin is FDA approved for specific uses, while CJC-1295 is not fda approved and treated as a research compound in the US. See each compound's full evidence breakdown for the underlying studies.